c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 148 products for "c-Met/HGFR".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Formula:C45H41FN10O5Color and Shape:SolidMolecular weight:820.87Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Formula:C29H49N4O10PPurity:98.01%Color and Shape:SolidMolecular weight:644.69Norleual
CAS:Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.Formula:C41H58N8O7Purity:98%Color and Shape:SolidMolecular weight:774.95Narnatumab
CAS:Narnatumab (IMC-RON8) is a humanized antibody that targets the macrophage-stimulating receptor 1 (RON). Narnatumab blocks the binding of RON to its ligand, macrophage-stimulating protein (MSP), and inhibits receptor activation, thereby suppressing tumor cell proliferation and migration. It is being investigated for the treatment of advanced malignant solid tumors.Purity:>95%Color and Shape:LiquidMolecular weight:145.8 kDa (Predicted)c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Formula:C16H13N7OMolecular weight:319.11816c-Met-IN-18
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formula:C51H54N10O7Color and Shape:SolidMolecular weight:919.037LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formula:C18H11F3N4OPurity:99.58%Color and Shape:Yellow SolidMolecular weight:356.3PROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Formula:C51H50F2N6O13Color and Shape:SolidMolecular weight:992.97VEGFR-2/c-Met/EGFR-IN-2
VEGFR-2/c-Met/EGFR-IN-2 is an inhibitor targeting VEGFR-2, c-Met, and EGFR, with IC50 values of 0.32 μM, 0.021 μM, and 9.3 μM, respectively. Known as c-Met-IN-27, this compound inhibits the proliferation of cancer cells and demonstrates anti-angiogenic activity in vivo by suppressing neovascularization in the chick embryo chorioallantoic membrane (CAM) assay. It is applicable in research related to breast and lung cancers.Norleual TFA
Norleual TFA, Ang IV analog, inhibits HGF/c-Met (IC50: 3 pM), blocks AT4, and has strong antiangiogenic effects.Formula:C43H59F3N8O9Color and Shape:SolidMolecular weight:888.97SYN1143
CAS:SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Formula:C31H29FN4O5Purity:99.69%Color and Shape:SolidMolecular weight:556.5842Anti-Human HGF Antibody (7V7)
Anti-HGF Antibody (7V7) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HGF.PF-04217903 methanesulfonate
CAS:PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formula:C20H20N8O4SPurity:98%Color and Shape:SolidMolecular weight:468.49Anti-Human MSPR/RON/CD136 Antibody (H5B14)
Anti-MSPR/RON/CD136 Antibody (H5B14) is a functional neutralizing antibody against RON, inhibiting tumor cell invasiveness and significantly delaying colorectal cancer progression by downregulating the MSP/RON signaling axis.Anti-Human MSPR/RON/CD136 Antibody
Anti-MSPR/RON/CD136 Antibody is a mAb targeting CD136 that exerts anti-tumor effects by inhibiting RON receptor phosphorylation and downstream PI3K and MAPK pathways.Anti-Human HGFR/c-Met Antibody 2
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met.Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Formula:C34H34F2N4O6Purity:98.07% - 99.68%Color and Shape:SolidMolecular weight:632.6538Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H21Cl2FN6O2Purity:99.77%Color and Shape:SolidMolecular weight:503.356Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formula:C26H21F3N4O4Purity:99.67% - 99.75%Color and Shape:SolidMolecular weight:510.4645
